Quick Summary — HUM scores higher on quality with 8.5/10 vs ALHC's 7.9/10. ALHC trades at $13.64 while HUM trades at $320.88. Both analyzed daily using SEC EDGAR data across 13 institutional models.
HUM scores higher with a 8.5/10 quality rating vs ALHC's 7.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $13.64, ALHC trades +30.3% below its Bayesian DCF fair value of $17.78, while HUM at $320.88 trades +79.2% above its estimate of $66.77. HUM shows a wider gap between price and intrinsic value.
ALHC earns a Quality of Company score of 7.9/10 compared to HUM's 8.5/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
ALHC carries a SAFE value trap risk (18/100) while HUM shows LOW risk (28/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both ALHC and HUM operate in Healthcare Plans, which has 8 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare ALHC vs HUM differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.